{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/28",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.369,
        "x": 0.577,
        "y": 0.69
      },
      "kind": "callout",
      "text": "Successful Phase 2b will support advancement to Phase 3 while evaluating the potential for a precision medicine for DED",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "620970f1-ee6d-4e15-af42-91cb44f843ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.56,
        "w": 0.506,
        "x": 0.03,
        "y": 0.244
      },
      "kind": "chart",
      "text": "High responders: VAS change from baseline >20; OCS-02: 12 (18%); Vehicle: 3 (5%); *P=0.018",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "653aa351-a492-42f3-85f3-17893d98198e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.369,
        "w": 0.369,
        "x": 0.577,
        "y": 0.28
      },
      "kind": "list",
      "text": "Association between gene variants and global ocular discomfort score at treatment day 29 was tested:\nAmong the gene variants tested, one variant out of 4 showed significant effect on the response to OCS-02.\nPatients with this gene variant tended to have larger improvement vs other p < 0.0001\nOculis is planning to further validate OCS-02 biomarker in the upcoming Phase 2b study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79aad52d-77e0-400e-b177-ef6f3b2beb57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.476,
        "x": 0.052,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "Pre-specified exploratory pharmacogenetic analysis focused on the genes relevant to TNF pathway and Sjogren's syndrome",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d23c716-4066-45cb-8046-dc9f270356f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.22,
        "x": 0.025,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Presented at ARVO 2021 by KOL (Perez V.)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6fed9d6-4df5-481b-8147-dd01a7313599",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.097,
        "w": 0.66,
        "x": 0.025,
        "y": 0.037
      },
      "kind": "title",
      "text": "OCS-02 | Biomarker Identified for High Responders – Potential for Precision Medicine Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e535c9b-e410-42f7-a0ae-c06d3dd4b586",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 25,
      "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}